🇺🇸 FDA
Patent

US 9562039

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

granted A61KA61K31/4709A61K45/06

Quick answer

US patent 9562039 (Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities) held by Almirall, S.A. expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4709, A61K45/06, A61K9/0073, A61K9/0075